VBI Vaccines Hits Multi-Month High: What to do Now?

Over the past year, many companies that have been involved in developing COVID-19 vaccines have seen their stocks record significant gains. One of them is VBI Vaccines Inc (NASDAQ: VBIV), which is working on a COVID-19 vaccine as well. Over the course of the past month, the stock recorded gains of as much as 55%, and on Monday alone, it grew by 21%.


The latest rally in the stock could well be related to an update provided by the company back on January 23 with regards to its pair of COVID-19 vaccines. The vaccines in question are VBI 2901 and VBI 2902. VBI announced that VBI 2901 displayed strong immunogenicity and efficacy in a hamster challenge study.

On the other hand, the company announced that it is going to launch the Phase I/II study of the second vaccine VBI 2902 at some point in Q1 2021. These are major announcements and have resulted in considerable optimism in the markets.

4xsuUegJey9rTYmCZmsEf2f9lWWr9aqvLQTL9fRjiC1dmJSc31mWuQL Me6AFyfSugYR PlK8UFZ5J8AaXApRXSmKmUY4BZSR

Michael Rowels

Weekend Contributor. Writing for business and finance publishers has become his passion over the last decades after he completed a master's degree in Financial Management. Sharing some opinions and forecasts to thousands of readers is a routine job for him but he never promises to invest in one stock.

Michael Rowels has 964 posts and counting. See all posts by Michael Rowels